Charlie Foucar
@CharlieFoucar
Followers
85
Following
367
Media
0
Statuses
36
Assistant professor at the University of New Mexico. Interest in leukemia and MDS.
Joined August 2019
RT @TalhaBadarMD: ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL https://t.c….
ashpublications.org
Key PointsPharmacokinetic analysis of a novel oral ATO formulation in patients with APL shows bioequivalence with the IV formulation.No unanticipated toxic
0
2
0
RT @WolverHeme: LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML. Come listen to @Berninini @ajperissinotti @CharlieFo….
creators.spotify.com
In this episode, Bernie and Anthony are joined by Dr. Charlie Foucar and Dr. Anand Patel to review the interesting and controversy-filled saga of gemtuzumab in AML? Should we be using this agent in...
0
9
0
RT @TalhaBadarMD: 🚨🚨👉🏾 Latest paper from #COMMAND_consortium in American Journal of Hematology | Blood Research Journal | Wiley Online Libr….
onlinelibrary.wiley.com
Click on the article title to read more.
0
6
0
RT @UChicagoLeuk: Check out this new article led by @AlexandraRojek & @Anand_88_Patel reporting outcomes in R/R CBF-AML previously treated….
0
4
0
A master class in BCR::ABL1-like ALL. I learned so much and am humbled by how far we have to go in this disease.
pubmed.ncbi.nlm.nih.gov
Philadelphia-like (Ph-like) or BCR::ABL1-like acute lymphoblastic leukemia (ALL) is a common high-risk subtype of B-cell precursor ALL (B-ALL) characterized by a diverse range of genetic alterations...
0
0
2
RT @TalhaBadarMD: Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia .by….
0
34
0
RT @GomezDLeonMD: AML genomic data pooling between 🇺🇸MARROW consortium 🤝 🇲🇽GTLA led by @LugoMd to clarify the meaning of “hispanic” #ASH24.….
0
2
0
RT @GomezDLeonMD: Extremely proud of @BloodCellsByAle who was awarded the David M. Goldenberg CRTI award at #ASH24 for her recognition as a….
0
3
0
RT @mpdrc: Excited to run into #AMLSM stars @Anand_88_Patel & our own @MadelynBur22 from @AtriumHealthWFB Comprehensive Cancer Center at #A….
0
3
0
RT @TalhaBadarMD: #ASH24 Another very productive #ASH for COMMAND consortium. Presenting several abstracts on acute leukemia and myeloid di….
0
6
0
RT @RoloffGreg: Topline results studying brexu-cel in relapsed B-ALL, now out @JCO_ASCO. My thanks to @LoriMuffly and partners from 30+ cen….
ascopubs.org
PURPOSEOn the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration...
0
10
0
RT @UNMCCC: Today is the Lobo Cancer Challenge! More than 1600 people signed up this year to #uniteagainstcancer
0
3
0
RT @UNMCCC: Thank you KOAT for highlighting our Allogeneic Stem Cell transplant program and telling Ana's story. There's still time to supp….
koat.com
A new treatment is changing how doctors treat blood cancers in New Mexico.
0
2
0
RT @Anand_88_Patel: The final version of our @e_JHaem paper on intensive chemo strategies in CBF-AML is available! @AlexandraRojek #leusm….
onlinelibrary.wiley.com
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN)...
0
8
0
RT @Anand_88_Patel: Our analysis of intensive chemo (IC) in CBF-AML (200 pt) is out in @e_JHaem! Kudos to lead author @AlexandraRojek . We….
0
22
0
RT @UNMCCC: The UNM Comprehensive Cancer Center was strongly represented over the weekend at @btfoundation's Best of ASCO Conference in Al….
0
3
0
RT @Anand_88_Patel: A very nice paper in @BloodAdvances by Dr Wieduwilt on clinical trial endpoints in ALL studies and highlighting the het….
0
4
0